134 related articles for article (PubMed ID: 30802787)
1. Modified DCs and MSCs with HPV E7 antigen and small Hsps: Which one is the most potent strategy for eradication of tumors?
Bolhassani A; Shahbazi S; Agi E; Haghighipour N; Hadi A; Asgari F
Mol Immunol; 2019 Apr; 108():102-110. PubMed ID: 30802787
[TBL] [Abstract][Full Text] [Related]
2. Small Heat Shock Proteins B1 and B6: Which One is the Most Effective Adjuvant in Therapeutic HPV Vaccine?
Bolhassani A; Shahbazi S; Milani A; Nadji SA
IUBMB Life; 2018 Oct; 70(10):1002-1011. PubMed ID: 30171788
[TBL] [Abstract][Full Text] [Related]
3. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
4. Combination of Mechanical and Chemical Methods Improves Gene Delivery in Cell-based HIV Vaccines.
Soleymani S; Hadi A; Asgari F; Haghighipour N; Bolhassani A
Curr Drug Deliv; 2019; 16(9):818-828. PubMed ID: 31549593
[TBL] [Abstract][Full Text] [Related]
5. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines.
Shahbazi S; Bolhassani A
Int Immunopharmacol; 2018 Sep; 62():170-180. PubMed ID: 30015237
[TBL] [Abstract][Full Text] [Related]
6. Enhanced immunotherapeutic effect of modified HPV16 E7-pulsed dendritic cell vaccine by an adeno-shRNA-SOCS1 virus.
Zhu Y; Zheng Y; Mei L; Liu M; Li S; Xiao H; Zhu H; Wu S; Chen H; Huang L
Int J Oncol; 2013 Oct; 43(4):1151-9. PubMed ID: 23877655
[TBL] [Abstract][Full Text] [Related]
7. Combined E7-dendritic cell-based immunotherapy and human sodium/iodide symporter radioiodine gene therapy with monitoring of antitumor effects by bioluminescent imaging in a mouse model of uterine cervical cancer.
Jeon YH; Lee HW; Lee YL; Kim JE; Hwang MH; Jeong SY; Lee SW; Ahn BC; Ha JH; Lee J
Cancer Biother Radiopharm; 2011 Dec; 26(6):671-9. PubMed ID: 22091632
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients.
Ferrara A; Nonn M; Sehr P; Schreckenberger C; Pawlita M; Dürst M; Schneider A; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):521-30. PubMed ID: 12898233
[TBL] [Abstract][Full Text] [Related]
10. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7.
Dell K; Klein C; Gissmann L
Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528
[TBL] [Abstract][Full Text] [Related]
11. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity.
Wang TL; Ling M; Shih IM; Pham T; Pai SI; Lu Z; Kurman RJ; Pardoll DM; Wu TC
Gene Ther; 2000 May; 7(9):726-33. PubMed ID: 10822298
[TBL] [Abstract][Full Text] [Related]
12. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
Mohit E; Bolhassani A; Zahedifard F; Taslimi Y; Rafati S
Scand J Immunol; 2012 Jan; 75(1):27-37. PubMed ID: 21916914
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours.
Chandy AG; Nurkkala M; Josefsson A; Eriksson K
Vaccine; 2007 Aug; 25(32):6037-46. PubMed ID: 17629599
[TBL] [Abstract][Full Text] [Related]
14. Vaccination efficacy with marrow mesenchymal stem cell against cancer was enhanced under simulated microgravity.
Li J; Chen J; Li X; Qian Y
Biochem Biophys Res Commun; 2017 Apr; 485(3):606-613. PubMed ID: 28238782
[TBL] [Abstract][Full Text] [Related]
15. The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity.
Ahn YH; Hong SO; Kim JH; Noh KH; Song KH; Lee YH; Jeon JH; Kim DW; Seo JH; Kim TW
Clin Exp Immunol; 2015 Jul; 181(1):164-78. PubMed ID: 25753156
[TBL] [Abstract][Full Text] [Related]
16. Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments.
Kang TH; Lee JH; Noh KH; Han HD; Shin BC; Choi EY; Peng S; Hung CF; Wu TC; Kim TW
Int J Cancer; 2007 Apr; 120(8):1696-703. PubMed ID: 17230516
[TBL] [Abstract][Full Text] [Related]
17. Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.
Talebi S; Bolhassani A; Azad TM; Arashkia A; Modaresi MH
Protein Pept Lett; 2017; 24(3):190-196. PubMed ID: 28000571
[TBL] [Abstract][Full Text] [Related]
18. Fungal mannosylation enhances human papillomavirus 16 E7 therapeutic immunity against TC-1 tumors.
Wang Z; Wei C; Zhang Y; Wang W; Zhou Z; Xiao G
Oncol Rep; 2018 Jan; 39(1):425-432. PubMed ID: 29115562
[TBL] [Abstract][Full Text] [Related]
19. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin.
Mansilla C; Berraondo P; Durantez M; Martínez M; Casares N; Arribillaga L; Rudilla F; Fioravanti J; Lozano T; Villanueva L; Sarobe P; Borrás F; Leclerc C; Prieto J; Lasarte JJ
Int J Cancer; 2012 Aug; 131(3):641-51. PubMed ID: 21898393
[TBL] [Abstract][Full Text] [Related]
20. Different dendritic cells-based vaccine constructs influence HIV-1 antigen-specific immunological responses and cytokine generation in virion-exposed splenocytes.
Milani A; Agi E; Hassan Pouriayevali M; Motamedi-Rad M; Motevalli F; Bolhassani A
Int Immunopharmacol; 2022 Dec; 113(Pt A):109406. PubMed ID: 36461600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
